NUVL Projected Dividend Yield

Nuvalent Inc ( NASDAQ : NUVL )

Nuvalent is a biopharmaceutical company. Co.'s product candidate, NVL-520, is a ROS proto-oncogene 1 (ROS1)-selective inhibitor designed with the aim to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of available ROS1 tyrosine kinase inhibitors. Co.'s another product candidate, NVL-655, is a brain-penetrant anaplastic lymphoma kinase (ALK)-selective inhibitor, designed with the aim to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that may limit the use of first-, second-, and third-generation ALK inhibitors.

21 YEAR PERFORMANCE RESULTS